00858.HK
Extrawell Pharmaceutical Holdings Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 0.08
+0.00%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 106.9M | 51.5M | 55.4M | 59.1M | 72.6M |
| Cost of Revenue | 62.3M | 28.7M | 33.6M | 30.3M | 41.4M |
| Gross Profit | 44.6M | 22.7M | 21.9M | 28.8M | 31.1M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | 194.0K | 881.0K |
| SG&A Expense | 65.2M | 32.5M | 30.9M | 35.3M | 42.4M |
| General & Admin Expense | 32.0M | — | 21.6M | 22.2M | 25.7M |
| Selling & Marketing Expense | 15.3M | — | 9.3M | 13.2M | 16.7M |
| Other Expenses | (169.0K) | — | (117.0K) | — | 437.0K |
| Total Operating Expenses | 65.1M | 32.5M | 30.8M | 35.5M | 42.3M |
| Cost and Expenses | 127.4M | 61.2M | 64.3M | 65.8M | 83.7M |
| Operating Income (EBIT) | (20.4M) | (9.7M) | (8.9M) | (6.5M) | (11.2M) |
| Non-Operating | |||||
| Interest Income | 9.1M | 4.1M | 5.0M | 5.7M | 3.0M |
| Interest Expense | 48.2M | 26.1M | 22.1M | 18.8M | 15.6M |
| Net Interest Income | (39.2M) | (22.0M) | (17.1M) | (13.1M) | (12.6M) |
| Other Non-Op Income/Expense | (741.1M) | (976.5M) | 233.6M | (153.0M) | 145.9M |
| Non-Operating Income (excl Interest) | (257.2M) | — | (255.7M) | 131.9M | (157.7M) |
| EBT (Pre-Tax Income) | (760.8M) | (986.2M) | 224.7M | (159.5M) | 134.8M |
| Income Tax Expense | (7.3M) | (8.4M) | 1.2M | 2.1M | 1.1M |
| Bottom Line | |||||
| Net Income | (757.1M) | (979.7M) | 222.6M | (162.9M) | 129.3M |
| Earnings from Cont. Ops | (754.2M) | (977.8M) | 223.6M | (161.6M) | 129.8M |
| Earnings from Discont. Ops | (105.0K) | — | (105.0K) | — | — |
| Bottom Line Net Income | (735.1M) | (979.7M) | 244.6M | (162.9M) | 144.8M |
| Per Share | |||||
| Basic EPS | (HK$0.29) | (HK$0.40) | HK$0.09 | (HK$0.07) | HK$0.05 |
| Diluted EPS | (HK$0.31) | (HK$0.40) | HK$0.07 | (HK$0.07) | HK$0.04 |
| Revenue Per Share | HK$0.04 | HK$0.02 | HK$0.02 | HK$0.02 | HK$0.03 |
| Shares | |||||
| Basic Shares Outstanding | 2.6B | 2.5B | 2.4B | 2.4B | 2.4B |
| Diluted Shares Outstanding | 2.6B | 2.5B | 3.3B | 2.4B | 3.3B |
| Profitability Metrics | |||||
| EBITDA | 254.6M | (1.8M) | 255.1M | (129.5M) | 155.2M |
| D&A | 15.3M | 7.9M | 8.3M | 8.9M | 8.7M |
| EBIT | 239.3M | (9.7M) | 246.8M | (138.4M) | 146.5M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026